HUTCHMED (China) (HCM) – Hot FDA News
-
HUTCHMED (China) (HCM) Receives CRL for Surufatinib for Treatment of Advanced Neuroendocrine
-
Hutchison China MediTech (HCM) Reports Surufatinib Phase III SANET-p Study Has Already Achieved Primary Endpoint in Advanced Pancreatic Neuroendocrine Tumors in China; Will Stop Early
Back to HCM Stock Lookup
